体外冲击波治疗带状疱疹后神经痛的疗效与安全性:随机对照试验研究方案
本研究为单中心、单盲随机对照试验方案,拟纳入98例带状疱疹后神经痛患者,按1:1随机分为常规治疗组和常规治疗联合体外冲击波治疗组。主要结局为视觉模拟量表评估的疼痛强度,次要结局包括生活质量、焦虑抑郁及睡眠质量,并检测肿瘤坏死因子-α和白细胞介素-6以探索生化机制。
要点
- 拟评估体外冲击波治疗带状疱疹后神经痛的疗效与安全性
- 主要结局为VAS疼痛强度,次要结局含生活质量、心理状态和睡眠
- 将检测TNF-α和IL-6探索体外冲击波治疗的潜在生化机制
核心结论
- 该随机对照试验将评估体外冲击波治疗带状疱疹后神经痛的有效性和安全性,为其临床应用提供证据并探索潜在生化机制。
研究设计与样本
- 单中心、单盲随机对照试验,拟纳入98例参与者,按1:1比例随机分为对照组和试验组。
- 对照组接受包括药物治疗和侵入性介入治疗的常规治疗,试验组在常规治疗基础上加用体外冲击波治疗。
关键数值与推荐
- 主要结局为视觉模拟量表评估的疼痛强度。
- 次要结局包括36项简短健康调查评估的生活质量、自评焦虑量表和自评抑郁量表评估的焦虑抑郁状态、匹兹堡睡眠质量指数评估的睡眠质量。
- 在基线及第1、4、12周由对随机分组不知情的评估者收集数据。
- 在体外冲击波治疗前后评估血浆肿瘤坏死因子-α和白细胞介素-6水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postherpetic neuralgia (PHN) is one of the most common types of chronic neuropathic pain, which seriously affects quality of the life because of pain severity and poor response to the currently available treatments. The main strategies for PHN management are medication and invasive interventional therapies; however, these approaches have many adverse effects, so it is important to find another effective and safe treatment for PHN. METHODS: A single-center, single-blind randomized clinical trial will evaluate 98 study participants randomized in a 1:1 ratio into control and experimental groups. The control group will receive conventional treatment including medication therapy and invasive interventional therapy. The experimental group will receive extracorporeal shockwave therapy (ESWT) in addition to conventional therapy. The primary outcome is pain intensity assessed on a visual analogue scale (VAS); the secondary outcomes are the following: quality of life assessed by the 36-Item Short-Form Health Survey (SF-36), psychological state for anxiety and depression measured by the Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS), and sleep quality measured by the Pittsburgh Sleep Quality Index (PSQI). Assessors blinded to the randomization will collect data during the intervention period at baseline and weeks 1, 4, and 12. The plasma levels of tumor necrosis factor-α and interleukin-6 will be assessed before and after ESWT to explore the biochemical mechanisms of ESWT in the treatment of PHN. DISCUSSION: This randomized controlled trial will evaluate the effectiveness and safety of ESWT in patients with PHN and thus will provide clinical evidence for its use in the management of PHN and explore the potential biochemical mechanisms of this treatment. TRIAL REGISTRATION: www.ChiCTR.org.cn , identifier: ChiCTR1900025828. Registered on 10 September 2019.
引用
- Chen L, Zhou R, Sun F, et al. Efficacy and safety of the extracorporeal shockwave therapy in patients with postherpetic neuralgia: study protocol of a randomized controlled trial. Trials. 2020. PMID: 32641142. doi:10.1186/s13063-020-04564-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。